Effect of infliximab on small bowel stenoses in patients with Crohn's disease.
OBJECTIVE
To assess prospectively small bowel stenoses in Crohn's disease (CD) patients treated with infliximab using Small Intestine Contrast Ultrasonography (SICUS).


METHODS
Twenty patients (M 12, age, 42.7 +/- 11.8 years), 15 of whom showed obstructive symptoms indicating the presence of small bowel stenosis, and 5 without stenosis, were treated with infliximab (5 mg/kg at wk 0, 2, 6 and 5 mg/kg every 8 wk thereafter) for steroid refractoriness, fistulizing disease, or to avoid high-risk surgery. SICUS was performed at the induction phase and at regular time intervals during the follow-up period of 34.7 +/- 16.1 mo (range 7-58). Small bowel stenoses were detected by SICUS, endoscopy and MRI.


RESULTS
In no case was progression of stenoses or the appearance of new ones seen. Of the 15 patients with stenosis, 5 stopped treatment after the induction phase (2 for no response, 3 for drug intolerance, one of whom showed complete regression of one stenosis). Among the remaining 10 patients, a complete regression of 8 stenoses (1 stenosis in 5 patients and 3 stenoses in one patient) was observed after 6-22 infliximab infusions.


CONCLUSIONS
In patients with CD treated with infliximab we observed: (a) No progression of small bowel stenosis and no appearance of new ones, (b) Complete regression of 1/22 stenosis after the induction phase and of 8/15 (53.3%) stenosis after 6-22 infusions during maintenance therapy.
Pallotta
Nadia
N
Department of Clinical Science, University of Rome Sapienza, Rome COU Gastroenterology S. Camillo De Lellis Hospital Rieti, Rome 00168, Italy.
Barberani
Fausto
F
Hassan
Naima-Abdulkadir
NA
Guagnozzi
Danila
D
Vincoli
Giuseppina
G
Corazziari
Enrico
E
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D003251:Constriction, Pathologic / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003424:Crohn Disease / Q000000981:diagnostic imaging / Q000473:pathology*; D005260:Female; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007421:Intestine, Small / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014463:Ultrasonography
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab